Phaseline

Companies › Nimbus Wadjet

Nimbus Wadjet: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NDI-219216
WRN helicase inhibitor
WRNPhase 1Advanced Solid Tumors CancerOct 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06898450NDI-219216Phase 1Advanced Solid Tumors CancerOncologyOct 2031

Targets

WRN (1)

Companies with the same targets

Vividion Therapeutics Eikon Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.